You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

Citation Tools

Article menu

Download PDFPDF

Rheumatoid arthritis
Original article
Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Alten R, Batko B, Hala T, et al
Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54
RMD Open 2019;5:e000876. doi: 10.1136/rmdopen-2018-000876